VIA Pharmaceuticals, Inc. (VIAP)

[mlkrborn]

Completion and up 4 cents!
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Date : 12/03/2009 @ 9:00AM
Source : PR Newswire
Stock : (VIAP)
Quote : 0.34 0.04 (13.33%) @ 7:22AM




VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291

Trial Utilizes Positron Emission Tomography with Flurodeoxyglucose Tracer (FDG-PET) Non Invasive Imaging

SAN FRANCISCO, Dec. 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (NASDAQ:VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com/.